FOENIX / TAS120
29 Nov 2021
Trial Summary
This is an open-label, multinational, parallel 2-arm, randomized Phase 3 study evaluating the efficacy and safety of futibatinib versus gemcitabine-cisplatin chemotherapy as first-line treatment of patients with advanced, metastatic, or recurrent unresectable iCCA harboring FGFR2 gene rearrangements
Acronym:
FOENIX / TAS120
ACTRN/NCT /ethics:
NCT04093362
Scientific title:
A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3
Sponsor / Cooperative group:
Taiho Oncology, Inc.
Trial & Patient Characteristics
| Cancer Type | Other |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | Advanced Cholangeiocarcinoma FGFR2 gene rearrangements |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2020-03-01 |
| Anticipated End Date | 2025-04-01 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Hannah Adelson |
| Hannah.adelson@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Professor Chris Karapetis |
| Recruitment Status | Recruiting |